Louis Moore Bacon's ASND Position Overview
Louis Moore Bacon (via Moore Capital Management, Lp) currently holds 125,000 shares of Ascendis Pharma A/S (ASND) worth $26.66 M, representing 0.38% of the portfolio. First purchased in 2019-Q4, this medium-term investment has been held for 10 quarters.
Based on 13F filings, Louis Moore Bacon has maintained a strategic position in ASND, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2025, adding 70,000 shares. Largest reduction occurred in Q1 2020, reducing 37,133 shares.
Analysis based on 13F filings available since 2013 Q2
Louis Moore Bacon's Ascendis Pharma A/S (ASND) Holding Value Over Time
Track share changes against reported price movement
Quarterly Ascendis Pharma A/S (ASND) Trades by Louis Moore Bacon
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +35,000 | Add 38.89% | 125,000 | $213.24 |
| Q3 2025 | -30,000 | Reduce 25.00% | 90,000 | $198.81 |
| Q2 2025 | +30,000 | Add 33.33% | 120,000 | $172.60 |
| Q1 2025 | +70,000 | Add 350.00% | 90,000 | $155.86 |
| Q4 2024 | -20,000 | Reduce 50.00% | 20,000 | $137.67 |
| Q3 2024 | +40,000 | New Buy | 40,000 | $149.31 |
| Q1 2023 | -20,000 | Sold Out | 0 | $0.00 |
| Q4 2022 | +20,000 | New Buy | 20,000 | $122.13 |
| Q1 2020 | -37,133 | Sold Out | 0 | $0.00 |
| Q4 2019 | +37,133 | New Buy | 37,133 | $139.12 |
Louis Moore Bacon's Ascendis Pharma A/S Investment FAQs
Louis Moore Bacon first purchased Ascendis Pharma A/S (ASND) in Q4 2019, acquiring 37,133 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Louis Moore Bacon has held Ascendis Pharma A/S (ASND) for 10 quarters since Q4 2019.
Louis Moore Bacon's largest addition to Ascendis Pharma A/S (ASND) was in Q1 2025, adding 90,000 shares worth $14.03 M.
According to the latest 13F filing for Q4 2025, Louis Moore Bacon's firm, Moore Capital Management, Lp, owns 125,000 shares of Ascendis Pharma A/S (ASND), valued at approximately $26.66 M.
As of the Q4 2025 filing, Ascendis Pharma A/S (ASND) represents approximately 0.38% of Louis Moore Bacon's publicly disclosed stock portfolio, making it one of their key holdings.
Louis Moore Bacon's peak holding in Ascendis Pharma A/S (ASND) was 125,000 shares, as reported at the end of Q4 2025.